A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
Completed · Phase 1/Phase 2
Conditions studied: Advanced Unresectable Solid Tumors, BRAF-mutated Tumors
In brief
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.
Key facts
- Study ID
- NCT02428712
- Run by
- Fore Biotherapeutics
- People needed
- 113
- Starts
- 2015-04-01
- Expected to finish
- 2024-07-12
- Last updated by the study team
- 2025-07-29
Who can join
Age: 10 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- HonorHealth — Scottsdale, Arizona, United States
- St. Joseph's Hospital at Orange — Orange, California, United States
- Stanford Hospitals and Clinics — Stanford, California, United States
- University of Miami — Miami, Florida, United States
- Community Health Network — Indianapolis, Indiana, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Capital Regional Medical Center — Jefferson City, Missouri, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Baptist Cancer Center — Memphis, Tennessee, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Texas Children's Hospital (Baylor College of Medicine) — Houston, Texas, United States
- Huntsman Cancer Institute — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.